Aiming drug discovery at lysophosphatidic acid targets

British Journal of Pharmacology

Volumn 161, Issue 2, 2010, Pages 241-270

  Tigyi, Gabor ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

alkyl glycerophosphate; cyclic phosphatidic acid; endothelial differentiation gene; GPR23; GPR87; GPR92; lysophospholipid; P2Y10; P2Y5; PPAR

Indexed keywords

AUTOTAXIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 35; G PROTEIN COUPLED RECEPTOR 87; G PROTEIN COUPLED RECEPTOR 92; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PURINERGIC P2Y10 RECEPTOR; PURINERGIC P2Y5 RECEPTOR; PURINERGIC P2Y9 RECEPTOR; PURINERGIC RECEPTOR; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

BONE METABOLISM; CANCER RADIOTHERAPY; CANCER RESISTANCE; DEGENERATIVE DISEASE; DRUG TARGETING; FIBROSIS; GENITAL SYSTEM DISEASE; HUMAN; IMMUNITY; IN VIVO STUDY; INFECTION; INTRACELLULAR SIGNALING; LIPOGENESIS; MALIGNANT TRANSFORMATION; METASTASIS; NERVE FIBER C; NERVOUS SYSTEM; OVARY CANCER; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR DISEASE;

ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; LYSOPHOSPHOLIPIDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 77956034731     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00815.x     Document Type: Review

References (300)

1. Ahn DK, Lee SY, Han SR, Ju JS, Yang GY, Lee MK et al. (2009). Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain 146 : 114 120.
2. Alexander JS, Patton WF, Christman BW, Cuiper LL, Haselton FR (1998). Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro. Am J Physiol 274 (1 Pt 2 H115 H122.
3. Amisten S, Braun OO, Bengtsson A, Erlinge D (2008). Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 122 : 47 57.
4. Angeli V, Llodra J, Rong JX, Satoh K, Ishii S, Shimizu T et al. (2004). Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21 : 561 574.
5. Aoki J, Inoue A, Makide K, Saiki N, Arai H (2007). Structure and function of extracellular phospholipase A1 belonging to the pancreatic lipase gene family. Biochimie 89 : 197 204.
6. Aoki J, Inoue A, Okudaira S (2008). Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781 : 513 518.
7. Asada M, Yoshida M, Suzuki T, Hatachi Y, Sasaki T, Yasuda H et al. (2009). Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antiviral Res 83 : 191 200.
8. Bagga S, Price KS, Lin DA, Friend DS, Austen KF, Boyce JA (2004). Lysophosphatidic acid accelerates the development of human mast cells. Blood 104 : 4080 4087.
9. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ (2001). Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem 292 : 287 295.
10. Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM et al. (2002). Plasma lysophosphatidic Acid concentration and ovarian cancer. JAMA 287 : 3081 3082.
11. Baker PR, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C et al. (2005). Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem 280 : 42464 42475.
12. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H et al. (2006). Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 281 : 22786 22793.
13. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K (2000). Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett 478 : 159 165.
14. Bauer M, Retzer M, Wilde JI, Maschberger P, Essler M, Aepfelbacher M et al. (1999). Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood 94 : 1665 1672.
15. Beck HP, Kohn T, Rubenstein S, Hedberg C, Schwandner R, Hasslinger K et al. (2008). Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett 18 : 1037 1041.
16. Birgbauer E, Chun J (2006). New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 63 : 2695 2701.
17. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT et al. (2006). Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 82 : 175 183.
18. Brigl M, Brenner MB (2004). CD1: antigen presentation and T cell function. Annu Rev Immunol 22 : 817 890.
19. Budnik LT, Mukhopadhyay AK (1997). Functional lysophosphatidic acid receptor in bovine luteal cells. FEBS Lett 419 : 4 8.
20. Carnevale KA, Cathcart MK (2001). Calcium-independent phospholipase A(2) is required for human monocyte chemotaxis to monocyte chemoattractant protein 1. J Immunol 167 : 3414 3421.
21. Caverzasio J, Palmer G, Suzuki A, Bonjour JP (2000). Evidence for the involvement of two pathways in activation of extracellular signal-regulated kinase (Erk) and cell proliferation by Gi and Gq protein-coupled receptors in osteoblast-like cells. J Bone Miner Res 15 : 1697 1706.
22. Chan LC, Peters W, Xu Y, Chun J, Farese RV, Jr., Cases S (2007). LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J Leukoc Biol 82 : 1193 1200.
23. Chemin J, Patel A, Duprat F, Zanzouri M, Lazdunski M, Honore E (2005). Lysophosphatidic acid-operated K+ channels. J Biol Chem 280 : 4415 4421.
24. Cheng Y, Makarova N, Tsukahara R, Guo H, E S, Farrar P et al. (2009). Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARγ but Not LPA1 or LPA2 GPCR. Cell Signal 12 : 1874 1884.
25. Chettibi S, Lawrence AJ, Stevenson RD, Young JD (1994). Effect of lysophosphatidic acid on motility, polarisation and metabolic burst of human neutrophils. FEMS Immunol Med Microbiol 8 : 271 281.
26. Choi JW, Lee CW, Chun J (2008). Biological roles of lysophospholipid receptors revealed by genetic null mice: an update. Biochim Biophys Acta 1781 : 531 539.
27. Chua CC, Hamdy RC, Chua BH (1998). Upregulation of endothelin-1 production by lysophosphatidic acid in rat aortic endothelial cells. Biochim Biophys Acta 1405 : 29 34.
28. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W et al. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54 : 265 269.
29. Clair T, Koh E, Ptaszynska M, Bandle RW, Liotta LA, Schiffmann E et al. (2005). L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis 4 : 5.
30. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J (2000). Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 97 : 13384 13389.
31. van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH (1989). Lysophosphatidate-induced cell proliferation: Identification and dissection of signaling pathways mediated by G proteins. Cell 59 : 45 54.
32. van Corven EJ, van Rijswijk A, Jalink K, van der Bend RL, van Blitterswijk WJ, Moolenaar WH (1992). Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Dependence on acyl-chain length and inhibition by suramin. Biochem J 281 (Pt 1 163 169.
33. Croset M, Brossard N, Polette A, Lagarde M (2000). Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 345 (Pt 1 61 67.
34. Daaka Y (2002). Mitogenic action of LPA in prostate. Biochim Biophys Acta 1582 : 265 269.
35. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM et al. (1999a). High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17 : 799 808.
36. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G et al. (1999b). MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 73 : 372 382.
37. Davies SS, Pontsler AV, Marathe GK, Harrison KA, Murphy RC, Hinshaw JC et al. (2001). Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem 276 : 16015 16023.
38. De Libero G, Donda A, Gober HJ, Manolova V, Mazorra Z, Shamshiev A et al. (2002). A new aspect in glycolipid biology: glycosphingolipids as antigens recognized by T lymphocytes. Neurochem Res 27 : 675 685.
39. Deng W, Shuyu E, Tsukahara R, Valentine WJ, Durgam G, Gududuru V et al. (2007). The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 132 : 1834 1851.
40. Dennis J, Nogaroli L, Fuss B (2005). Phosphodiesterase-Ialpha/autotaxin (PD-Ialpha/ATX): a multifunctional protein involved in central nervous system development and disease. J Neurosci Res 82 : 737 742.
41. Dennis J, White MA, Forrest AD, Yuelling LM, Nogaroli L, Afshari FS et al. (2008). Phosphodiesterase-Ialpha/autotaxin's MORFO domain regulates oligodendroglial process network formation and focal adhesion organization. Mol Cell Neurosci 37 : 412 424.
42. Diep QN, Schiffrin EL (2001). Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats. Hypertension 38 : 249 254.
43. Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D (2006). Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours. Eur J Cancer 42 : 674 679.
44. Dottori M, Leung J, Turnley AM, Pebay A (2008). Lysophosphatidic acid inhibits neuronal differentiation of neural stem/progenitor cells derived from human embryonic stem cells. Stem Cells 26 : 1146 1154.
45. Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K et al. (2005). Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 48 : 4919 4930.
46. Dziak R, Yang BM, Leung BW, Li S, Marzec N, Margarone J et al. (2003). Effects of sphingosine-1-phosphate and lysophosphatidic acid on human osteoblastic cells. Prostaglandins Leukot Essent Fatty Acids 68 : 239 249.
47. E S, Lai YJ, Tsukahara R, Chen CS, Fujiwara Y, Yue J et al. (2009). Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. J Biol Chem 284 : 14558 14571.
48. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H et al. (1998). Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95 : 8806 8811.
49. English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN et al. (1999). Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 8 : 627 634.
50. Estivill-Torrus G, Llebrez-Zayas P, Matas-Rico E, Santin L, Pedraza C, De Diego I et al. (2008). Absence of LPA1 signaling results in defective cortical development. Cereb Cortex 18 : 938 950.
51. Evans RM (2005). The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 19 : 1429 1438.
52. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ et al. (2000). Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein- mediated activation of mitogen-activated protein kinase. Biochem J 352 : 135 143.
53. Fells JI, Tsukahara R, Fujiwara Y, Liu J, Perygin DH, Osborne DA et al. (2008). Identification of non-lipid LPA3 antagonists by virtual screening. Bioorg Med Chem 16 : 6207 6217.
54. Fells JI, Tsukahara R, Liu J, Tigyi G, Parrill AL (2009). Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem 17 : 7457 7464.
55. Ferry G, Moulharat N, Pradere JP, Desos P, Try A, Genton A et al. (2008). S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 327 : 809 819.
56. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, Baker DL et al. (2001). Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 60 : 776 784.
57. Fishman DA, Liu Y, Ellerbroek SM, Stack MS (2001). Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61 : 3194 3199.
58. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995). 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 : 803 812.
59. Fotopoulou S, Oikonomou N, Grigrorieva E, Nikitopoulou I, Paparountas T, Thanassopoulou A et al. (2010). ATX expression and LPA signaling are vital for the development of the nervous system. Dev Biol 339 : 451 464.
60. Fox MA, Colello RJ, Macklin WB, Fuss B (2003). Phosphodiesterase-Ialpha/ autotaxin: a counteradhesive protein expressed by oligodendrocytes during onset of myelination. Mol Cell Neurosci 23 : 507 519.
61. Fox MA, Alexander JK, Afshari FS, Colello RJ, Fuss B (2004). Phosphodiesterase-I alpha/autotaxin controls cytoskeletal organization and FAK phosphorylation during myelination. Mol Cell Neurosci 27 : 140 150.
62. Friedman P, Haimovitz R, Markman O, Roberts MF, Shinitzky M (1996). Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase D. J Biol Chem 271 : 953 957.
63. Fueller M, Wang DA, Tigyi G, Siess W (2003). Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. Cell Signal 15 : 367 375.
64. Fujita R, Kiguchi N, Ueda H (2007). LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 50 : 351 355.
65. Fujiwara Y (2008). Cyclic phosphatidic acid - a unique bioactive phospholipid. Biochim Biophys Acta 1781 : 519 524.
66. Fujiwara Y, Sardar V, Tokumura A, Baker D, Murakami-Murofushi K, Parrill A et al. (2005). Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J Biol Chem 280 : 35038 35050.
67. Fuss B, Baba H, Phan T, Tuohy VK, Macklin WB (1997). Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function. J Neurosci 17 : 9095 9103.
68. Garg SK, Valente E, Greco E, Santucci MB, De Spirito M, Papi M et al. (2006). Lysophosphatidic acid enhances antimycobacterial activity both in vitro and ex vivo. Clin Immunol 121 : 23 28.
69. Gil OD, Lee C, Ariztia EV, Wang FQ, Smith PJ, Hope JM et al. (2008). Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner. Gynecol Oncol 108 : 361 369.
70. Glatt S, Halbauer D, Heindl S, Wernitznig A, Kozina D, Su KC et al. (2008). hGPR87 contributes to viability of human tumor cells. Int J Cancer 122 : 2008 2016.
71. Gobeil F, Jr., Bernier SG, Vazquez-Tello A, Brault S, Beauchamp MH, Quiniou C et al. (2003). Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J Biol Chem 278 : 38875 38883.
72. Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR et al. (1999a). Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 59 : 5370 5375.
73. Goetzl EJ, Kong Y, Mei B (1999b). Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 162 : 2049 2056.
74. Goetzl EJ, Kong Y, Voice JK (2000a). Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J Immunol 164 : 4996 4999.
75. Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, Karliner JS (2000b). Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem 275 : 14573 14578.
76. Greco E, Santucci MB, Sali M, De Angelis FR, Papi M, De Spirito M et al. (2010). Natural lysophospholipids reduce Mycobacterium tuberculosis-induced cytotoxicity and induce anti-mycobacterial activity by a phagolysosome maturation-dependent mechanism in A549 type II alveolar epithelial cells. Immunology 129 : 125 132.
77. Grey A, Banovic T, Naot D, Hill B, Callon K, Reid I et al. (2001). Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. Endocrinology 142 : 1098 1106.
78. Grey A, Chen Q, Callon K, Xu X, Reid IR, Cornish J (2002). The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase. Endocrinology 143 : 4755 4763.
79. Gugger M, White R, Song S, Waser B, Cescato R, Riviere P et al. (2008). GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Markers 24 : 41 50.
80. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N et al. (2006). Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147 : 4883 4892.
81. Hahn A, Heusinger-Ribeiro J, Lanz T, Zenkel S, Goppelt-Struebe M (2000). Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J Biol Chem 275 : 37429 37435.
82. Hama K, Aoki J, Inoue A, Endo T, Amano T, Motoki R et al. (2007). Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. Biol Reprod 77 : 954 959.
83. Hayashi K, Takahashi M, Nishida W, Yoshida K, Ohkawa Y, Kitabatake A et al. (2001). Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res 89 : 251 258.
84. Hecht JH, Weiner JA, Post SR, Chun J (1996). Ventricular Zone Gene-1 (vzg-1) Encodes a Lysophosphatidic Acid Receptor Expressed in Neurogenic Regions of the Developing Cerebral Cortex. J Cell Biol 135 : 1071 1083.
85. Heise CE, Santos WL, Schreihofer AM, Heasley BH, Mukhin YV, Macdonald TL et al. (2001). Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 60 : 1173 1180.
86. Herr DR, Chun J (2007). Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 8 : 155 167.
87. Hiramatsu T, Sonoda H, Takanezawa Y, Morikawa R, Ishida M, Kasahara K et al. (2003). Biochemical and molecular characterization of two phosphatidic acid-selective phospholipase A1s, mPA-PLA1alpha and mPA-PLA1beta. J Biol Chem 278 : 49438 49447.
88. Hiramoto T, Nemoto W, Kikuchi T, Fujita N (2002). Construction of hypothetical three-dimensional structure of P2Y1 receptor based on Fourier transform analysis. J Protein Chem 21 : 537 545.
89. Hiramoto T, Nonaka Y, Inoue K, Yamamoto T, Omatsu-Kanbe M, Matsuura H et al. (2004). Identification of endogenous surrogate ligands for human P2Y receptors through an in silico search. J Pharmacol Sci 95 : 81 93.
90. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K et al. (2009). LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol 112 : 215 223.
91. Horigome K, Hayakawa M, Inoue K, Nojima S (1987). Selective release of phospholipase A2 and lysophosphatidylserine-specific lysophospholipase from rat platelets. J Biochem 101 : 53 61.
92. Hornuss C, Hammermann R, Fuhrmann M, Juergens UR, Racke K (2001). Human and rat alveolar macrophages express multiple EDG receptors. Eur J Pharmacol 429 : 303 308.
93. Hosogaya S, Yatomi Y, Nakamura K, Ohkawa R, Okubo S, Yokota H et al. (2008). Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann Clin Biochem 45 (Pt 4 364 368.
94. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N et al. (2001). Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93 : 762 768.
95. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ (2004). Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene 23 : 122 129.
96. Hurst-Kennedy J, Boyan BD, Schwartz Z (2009). Lysophosphatidic acid signaling promotes proliferation, differentiation, and cell survival in rat growth plate chondrocytes. Biochim Biophys Acta 1793 : 836 846.
97. Hwang YS, Hodge JC, Sivapurapu N, Lindholm PF (2006). Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol Carcinog 45 : 518 529.
98. Idzko M, Laut M, Panther E, Sorichter S, Durk T, Fluhr JW et al. (2004). Lysophosphatidic acid induces chemotaxis, oxygen radical production, CD11b up-regulation, Ca2+ mobilization, and actin reorganization in human eosinophils via pertussis toxin-sensitive G proteins. J Immunol 172 : 4480 4485.
99. Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, Theodorescu D et al. (2000). Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 57 : 753 759.
100. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H (2004). Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 10 : 712 718.
101. Inoue M, Ma L, Aoki J, Chun J, Ueda H (2008a). Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 4 : 6.
102. Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H (2008b). Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 152 : 296 298.
103. Ishii I, Fukushima N, Ye X, Chun J (2004). Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73 : 321 354.
104. Ishii S, Noguchi K, Yanagida K (2009). Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat 89 : 57 65.
105. Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M (2009). Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 284 : 216 221.
106. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C et al. (2005). Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11 : 6300 6310.
107. Jin Y, Knudsen E, Wang L, Maghazachi AA (2003). Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization. Eur J Immunol 33 : 2083 2089.
108. Jo SH, Kim SD, Kim JM, Lee HY, Lee SY, Shim JW et al. (2008). Lysophosphatidylglycerol stimulates chemotactic migration in human natural killer cells. Biochem Biophys Res Commun 372 : 147 151.
109. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD (2008). Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 9 : 415 423.
110. Karagiosis SA, Karin NJ (2007). Lysophosphatidic acid induces osteocyte dendrite outgrowth. Biochem Biophys Res Commun 357 : 194 199.
111. Kazantseva A, Goltsov A, Zinchenko R, Grigorenko AP, Abrukova AV, Moliaka YK et al. (2006). Human hair growth deficiency is linked to a genetic defect in the phospholipase gene LIPH. Science 314 : 982 985.
112. Khandoga AL, Fujiwara Y, Goyal P, Pandey D, Tsukahara R, Bolen A et al. (2008). Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin. Platelets 19 : 415 427.
113. Khurana S, Tomar A, George SP, Wang Y, Siddiqui MR, Guo H et al. (2008). Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia. Exp Cell Res 314 : 530 542.
114. Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J (2003). Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 6 : 1292 1299.
115. Kinloch RA, Cox PJ (2005). New targets for neuropathic pain therapeutics. Expert Opin Ther Targets 9 : 685 698.
116. Kitamura H, Makide K, Okutani M, Arima N, Inoue A, Aoki J (2009). Identification of a novel lysophosphatidylserine receptor. In : Arai H (ed.). 4th International Conference on Phospholipase A2 and Lipid Mediators. Japan Science and Technology Agency : Tokyo, p. 132.
117. Kobayashi T, Yamano S, Murayama S, Ishikawa H, Tokumura A, Aono T (1994). Effect of lysophosphatidic acid on the preimplantation development of mouse embryos. FEBS Lett 351 : 38 40.
118. Kobayashi T, Tanaka-Ishii R, Taguchi R, Ikezawa H, Murakami-Murofushi K (1999). Existence of a Bioactive Lipid, Cyclic Phosphatidic Acid in Human Serum. Life Sci 56 : 245 253.
119. Koh JS, Lieberthal W, Heydrick S, Levine JS (1998). Lysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3-kinase signaling pathway. J Clin Invest 102 : 716 727.
120. Koike S, Keino-Masu K, Ohto T, Sugiyama F, Takahashi S, Masu M (2009). Autotaxin/lysophospholipase d-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac. J Biol Chem 284 : 33561 33570.
121. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S et al. (2006). Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 318 : 619 628.
122. Kunikata K, Yamano S, Tokumura A, Aono T (1999). Effect of lysophosphatidic acid on the ovum transport in mouse oviducts. Life Sci 65 : 833 840.
123. Lee MJ, Thangada S, Liu CH, Thompson BD, Hla T (1998). Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem 273 : 22105 22112.
124. Lee H, Liao JJ, Graeler M, Huang MC, Goetzl EJ (2002). Lysophospholipid regulation of mononuclear phagocytes. Biochim Biophys Acta 1582 : 175 177.
125. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006). GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281 : 23589 23597.
126. Lee CW, Rivera R, Dubin AE, Chun J (2007). LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem 282 : 4310 4317.
127. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A et al. (2008). Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 19 : 5435 5445.
128. Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J et al. (2009). New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol 29 : 472 479.
129. Lee-Kwon W, Kawano K, Choi JW, Kim JH, Donowitz M (2003). Lysophosphatidic acid stimulates brush border Na+/H+ exchanger 3 (NHE3) activity by increasing its exocytosis by an NHE3 kinase A regulatory protein-dependent mechanism. J Biol Chem 278 : 16494 16501.
130. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG et al. (2002). Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 : 6640 6650.
131. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 : 12953 12956.
132. Leslie DS, Vincent MS, Spada FM, Das H, Sugita M, Morita CT et al. (2002). CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med 196 : 1575 1584.
133. Leslie DS, Dascher CC, Cembrola K, Townes MA, Hava DL, Hugendubler LC et al. (2008). Serum lipids regulate dendritic cell CD1 expression and function. Immunology 125 : 289 301.
134. Li AC, Glass CK (2002). The macrophage foam cell as a target for therapeutic intervention. Nat Med 8 : 1235 1242.
135. Li S, Zhang J (2009). Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells. Biochem Biophys Res Commun 378 : 264 268.
136. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000). Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 : 523 531.
137. Li Y, Gonzalez MI, Meinkoth JL, Field J, Kazanietz MG, Tennekoon GI (2003). Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells. J Biol Chem 278 : 9585 9591.
138. Liliom K, Fischer DJ, Virag T, Sun G, Miller DD, Tseng JL et al. (1998). Identification of a novel growth factor-like lipid, 1-O-cis-alk-1′-enyl-2- lyso-sn-glycero-3-phosphate (alkenyl-GP) that is present in commercial sphingolipid preparations. J Biol Chem 273 : 13461 13468.
139. Liliom K, Tsukahara T, Tsukahara R, Zelman-Femiak M, Swiezewska E, Tigyi G (2006). Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs. Biochim Biophys Acta 1761 : 1506 1514.
140. Lim S, Jin CJ, Kim M, Chung SS, Park HS, Lee IK et al. (2006). PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 26 : 808 813.
141. Lin DA, Boyce JA (2005). IL-4 regulates MEK expression required for lysophosphatidic acid-mediated chemokine generation by human mast cells. J Immunol 175 : 5430 5438.
142. Lin CI, Chen CN, Chen JH, Lee H (2006). Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem 99 : 1216 1232.
143. Lin FT, Lai YJ, Makarova N, Tigyi G, Lin WC (2007). The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. J Biol Chem 282 : 37759 37769.
144. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F et al. (2009). Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15 : 539 550.
145. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ (2004). Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 101 : 11779 11784.
146. Lyons JM, Karin NJ (2001). A role for G protein-coupled lysophospholipid receptors in sphingolipid-induced Ca2+ signaling in MC3T3-E1 osteoblastic cells. J Bone Miner Res 16 : 2035 2042.
147. Ma L, Uchida H, Nagai J, Inoue M, Chun J, Aoki J et al. (2009). Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain. Mol Pain 5 : 64.
148. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC et al. (2003). Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 100 : 131 136.
149. Maghazachi AA (2003). G protein-coupled receptors in natural killer cells. J Leukoc Biol 74 : 16 24.
150. Matas-Rico E, Garcia-Diaz B, Llebrez-Zayas P, Lopez-Barroso D, Santin L, Pedraza C et al. (2008). Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Mol Cell Neurosci 39 : 342 355.
151. Meerschaert K, De Corte V, De Ville Y, Vandekerckhove J, Gettemans J (1998). Gelsolin and functionally similar actin-binding proteins are regulated by lysophosphatidic acid. EMBO J 17 : 5923 5932.
152. van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K et al. (2005). Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 280 : 21155 21161.
153. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP et al. (2006). Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26 : 5015 5022.
154. van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH (2008). Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett 266 : 203 208.
155. Meng Y, Graves L, Do TV, So J, Fishman DA (2004). Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes. Gynecol Oncol 95 : 488 495.
156. Mintzer E, Sargsyan H, Bittman R (2006). Lysophosphatidic acid and lipopolysaccharide bind to the PIP2-binding domain of gelsolin. Biochim Biophys Acta 1758 : 85 89.
157. Mishra RS, Carnevale KA, Cathcart MK (2008). iPLA2beta: front and center
158. Moller T, Musante DB, Ransom BR (1999). Lysophosphatidic acid-induced calcium signals in cultured rat oligodendrocytes. Neuroreport 10 : 2929 2932.
159. Muehlich S, Schneider N, Hinkmann F, Garlichs CD, Goppelt-Struebe M (2004). Induction of connective tissue growth factor (CTGF) in human endothelial cells by lysophosphatidic acid, sphingosine-1-phosphate, and platelets. Atherosclerosis 175 : 261 268.
160. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1 : 465 470.
161. Murakami M, Shiraishi A, Tabata K, Fujita N (2008). Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun 371 : 707 712.
162. Murakami-Murofushi K, Kaji K, Kano K, Fukuda M, Shioda M, Murofushi H (1993). Inhibition of cell proliferation by a unique lysophosphatidic acid, PHYLPA, isolated from Physarum polycephalum: signaling events of antiproliferative action by PHYLPA. Cell Struct Funct 18 : 363 370.
163. Murph MM, Nguyen GH, Radhakrishna H, Mills GB (2008). Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta 1781 : 547 557.
164. Murthi P, Barker G, Nowell CJ, Rice GE, Baker MS, Kalionis B et al. (2004). Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol Oncol 92 : 80 88.
165. Mutoh T, Chun J (2008). Lysophospholipid activation of G protein-coupled receptors. Subcell Biochem 49 : 269 297.
166. Nagle CA, Klett EL, Coleman RA (2009). Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res 50 (Suppl S74 S79.
167. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 : 229 240.
168. Nakane S, Tokumura A, Waku K, Sugiura T (2001). Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: distinct molecular species compositions. Lipids 36 : 413 419.
169. Nakasaki T, Tanaka T, Okudaira S, Hirosawa M, Umemoto E, Otani K et al. (2008). Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol 173 : 1566 1576.
170. Niwa H, Yamamura K, Miyazaki J (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 : 193 199.
171. Nogaroli L, Yuelling LM, Dennis J, Gorse K, Payne SG, Fuss B (2009). Lysophosphatidic acid can support the formation of membranous structures and an increase in MBP mRNA levels in differentiating oligodendrocytes. Neurochem Res 34 : 182 193.
172. Noguchi K, Ishii S, Shimizu T (2003). Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278 : 25600 25606.
173. Noguchi K, Herr D, Mutoh T, Chun J (2009). Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9 : 15 23.
174. Nonaka Y, Hiramoto T, Fujita N (2005). Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 337 : 281 288.
175. North EJ, Osborne DA, Bridson PK, Baker DL, Parrill AL (2009). Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs. Bioorg Med Chem 17 : 3433 3442.
176. Oh da Y, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY et al. (2008). Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283 : 21054 21064.
177. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J et al. (2003). Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64 : 994 1005.
178. Oka S, Ota R, Shima M, Yamashita A, Sugiura T (2010). GPR35 is a novel lysophosphatidic acid receptor. BBBRC 395 : 232 237.
179. Pamuklar Z, Lee JS, Cheng HY, Panchatcharam M, Steinhubl S, Morris AJ et al. (2008). Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol 28 : 555 561.
180. Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, Panchatcharam M et al. (2009). Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem 284 : 7385 7394.
181. Panther E, Idzko M, Corinti S, Ferrari D, Herouy Y, Mockenhaupt M et al. (2002). The influence of lysophosphatidic acid on the functions of human dendritic cells. J Immunol 169 : 4129 4135.
182. Parrill AL, Baker DL (2008). Autotaxin inhibition: challenges and progress toward novel anti-cancer agents. Anticancer Agents Med Chem 8 : 917 923.
183. Parrill AL, Echols U, Nguyen T, Pham TC, Hoeglund A, Baker DL (2008). Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Bioorg Med Chem 16 : 1784 1795.
184. Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K et al. (2008). G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 40 : 329 334.
185. Pasternack SM, von Kugelgen I, Muller M, Oji V, Traupe H, Sprecher E et al. (2009). In Vitro Analysis of LIPH Mutations Causing Hypotrichosis Simplex: Evidence Confirming the Role of Lipase H and Lysophosphatidic Acid in Hair Growth. J Invest Dermatol 129 : 2772 2776.
186. Perova T, Wasserman MJ, Li PP, Warsh JJ (2008). Hyperactive intracellular calcium dynamics in B lymphoblasts from patients with bipolar I disorder. Int J Neuropsychopharmacol 11 : 185 196.
187. Perova T, Kwan M, Li PP, Warsh JJ (2009). Differential modulation of intracellular Ca2+ responses in B lymphoblasts by mood stabilizers. Int J Neuropsychopharmacol 29 : 1 10.
188. Peyruchaud O (2009). Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer. Anticancer Agents Med Chem 9 : 381 391.
189. Pradere JP, Klein J, Gres S, Guigne C, Neau E, Valet P et al. (2007). LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 18 : 3110 3118.
190. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C et al. (1999). EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402 : 884 888.
191. Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD (2008). Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Cancer Res 6 : 352 363.
192. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA et al. (1999). Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5 : 3704 3710.
193. Qi C, Park JH, Gibbs TC, Shirley DW, Bradshaw CD, Ella KM et al. (1998). Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J Cell Physiol 174 : 261 272.
194. Rao S, Garrett-Sinha LA, Yoon J, Simon MC (1999). The Ets factors PU.1 and Spi-B regulate the transcription in vivo of P2Y10, a lymphoid restricted heptahelical receptor. J Biol Chem 274 : 34245 34252.
195. Retzer M, Essler M (2000). Lysophosphatidic acid-induced platelet shape change proceeds via Rho/Rho kinase-mediated myosin light-chain and moesin phosphorylation. Cell Signal 12 : 645 648.
196. Retzer M, Siess W, Essler M (2000). Mildly oxidised low density lipoprotein induces platelet shape change via Rho-kinase-dependent phosphorylation of myosin light chain and moesin. FEBS Lett 466 : 70 74.
197. Ricote M, Glass CK (2007). PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771 : 926 935.
198. Ridley AJ, Hall A (1992). The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70 : 389 399.
199. Ridley AJ, Hall A (1994). Signal transduction pathways regulating Rho-mediated stress fibre formation: requirement for a tyrosine kinase. EMBO J 13 : 2600 2610.
200. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A (1992). The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70 : 401 410.
201. Rivera R, Chun J (2008). Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol 160 : 25 46.
202. Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT et al. (1999). Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest 79 : 1227 1235.
203. Rosskopf D, Daelman W, Busch S, Schurks M, Hartung K, Kribben A et al. (1998). Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. Am J Physiol 274 (6 Pt 1 C1573 C1582.
204. Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G et al. (2003). Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108 : 741 747.
205. Roura-Mir C, Catalfamo M, Cheng TY, Marqusee E, Besra GS, Jaraquemada D et al. (2005). CD1a and CD1c activate intrathyroidal T cells during Graves' disease and Hashimoto's thyroiditis. J Immunol 174 : 3773 3780.
206. Rubenfeld J, Guo J, Sookrung N, Chen R, Chaicumpa W, Casolaro V et al. (2006). Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells. Am J Physiol Lung Cell Mol Physiol 290 : L66 L74.
207. Samadi N, Gaetano C, Goping IS, Brindley DN (2009). Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 28 : 1028 1039.
208. Sando JJ, Chertihin OI (1996). Activation of protein kinase C by lysophosphatidic acid: dependence on composition of phospholipid vesicles. Biochem J 317 (Pt 2 583 588.
209. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T et al. (2002). Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 277 : 21197 21206.
210. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB et al. (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4 : 1046 1052.
211. Sato T, Aoki J, Nagai Y, Dohmae N, Takio K, Doi T et al. (1997). Serine phospholipid-specific phospholipase A that is secreted from activated platelets. A new member of the lipase family. J Biol Chem 272 : 2192 2198.
212. Satoh Y, Ohkawa R, Nakamura K, Higashi K, Kaneko M, Yokota H et al. (2007). Lysophosphatidic acid protection against apoptosis in the human pre-B-cell line Nalm-6. Eur J Haematol 78 : 510 517.
213. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E et al. (2001). Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7 : 2396 2404.
214. Schulze C, Smales C, Rubin LL, Staddon JM (1997). Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J Neurochem 68 : 991 1000.
215. Schumacher KA, Classen HG, Spath M (1979). Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). Thromb Haemost 42 : 631 640.
216. Sheardown M, Messager S, Mathews E, Dickenson AH, Aparicio S, Brice NL (2004). Knockout of GPRr92 reveals key role in neuropathic and acute pain. In : Society of Neuroscience Abstracts. Society for Neuroscience : Washington, DC, p. 64.16.
217. Shimomura Y, Wajid M, Ishii Y, Shapiro L, Petukhova L, Gordon D et al. (2008). Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat Genet 40 : 335 339.
218. Shimomura Y, Wajid M, Petukhova L, Shapiro L, Christiano AM (2009a). Mutations in the lipase H gene underlie autosomal recessive woolly hair/hypotrichosis. J Invest Dermatol 129 : 622 628.
219. Shimomura Y, Wajid M, Zlotogorski A, Lee YJ, Rice RH, Christiano AM (2009b). Founder mutations in the lipase h gene in families with autosomal recessive woolly hair/hypotrichosis. J Invest Dermatol 129 : 1927 1934.
220. Sieling PA, Porcelli SA, Duong BT, Spada F, Bloom BR, Diamond B et al. (2000). Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 165 : 5338 5344.
221. Siess W (2006). Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiol Haemost Thromb 35 : 292 304.
222. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C et al. (1999). Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 96 : 6931 6936.
223. Simon MF, Chap H, Douste-Blazy L (1982). Human platelet aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: a new group of phospholipid mediators? Biochem Biophys Res Commun 108 : 1743 1750.
224. Simon MF, Chap H, Douste-Blazy L (1984). Platelet aggregating activity of lysophosphatidic acids is not related to their calcium ionophore properties. FEBS Lett 166 : 115 119.
225. So J, Navari J, Wang FQ, Fishman DA (2004). Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol 95 : 314 322.
226. So J, Wang FQ, Navari J, Schreher J, Fishman DA (2005). LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 97 : 870 878.
227. Sonoda H, Aoki J, Hiramatsu T, Ishida M, Bandoh K, Nagai Y et al. (2002). A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J Biol Chem 277 : 34254 34263.
228. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E et al. (1992). Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267 : 2524 2529.
229. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A et al. (1999). Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta 1440 : 194 204.
230. Sugo T, Tachimoto H, Chikatsu T, Murakami Y, Kikukawa Y, Sato S et al. (2006). Identification of a lysophosphatidylserine receptor on mast cells. Biochem Biophys Res Commun 341 : 1078 1087.
231. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC, Jr., LaPolla JP et al. (2004). Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13 : 1185 1191.
232. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N (2007). The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 363 : 861 866.
233. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z et al. (2008). The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14 : 45 54.
234. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M et al. (2006). Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281 : 25822 25830.
235. Tigyi G, Miledi R (1992). Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem 267 : 21360 21367.
236. Tigyi G, Parrill AL (2003). Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42 : 498 526.
237. Tigyi G, Dyer D, Matute C, Miledi R (1990). A serum factor that activates the phosphatidylinositol phosphate signaling system in Xenopus oocytes. Proc Natl Acad Sci USA 87 : 1521 1525.
238. Tokumura A, Fukuzawa K, Akamatsu Y, Yamada S, Suzuki T, Tsukatani H (1978a). Identification of vasopressor phospholipid in crude soybean lecithin. Lipids 13 : 468 472.
239. Tokumura A, Fukuzawa K, Tsukatani H (1978b). Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. Lipids 13 : 572 574.
240. Tokumura A, Fukuzawa K, Yamada S, Tsukatani H (1980). Stimulatory effect of lysophosphatidic acids on uterine smooth muscles of non-pregant rats. Arch Inter Pharmacodyn Ther 245 : 74 83.
241. Tokumura A, Iimori M, Nishioka Y, Kitahara M, Sakashita M, Tanaka S (1994). Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol 267 (1 Pt 1 C204 C210.
242. Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K (1999). Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of in vitro fertilization patients. Biol Reprod 61 : 159 199.
243. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K et al. (2002a). Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic acid-producing Enzyme, as Autotaxin, a Multifunctional Phosphodiesterase. J Biol Chem 277 : 39436 39442.
244. Tokumura A, Sinomiya J, Kishimoto S, Tanaka T, Kogure K, Sugiura T et al. (2002b). Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Biochem J 365 (Pt 3 617 628.
245. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A et al. (2009). Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 6 : 168 176.
246. Tomar A, George SP, Mathew S, Khurana S (2009). Differential effects of lysophosphatidic acid and phosphatidylinositol 4,5-bisphosphate on actin dynamics by direct association with the actin-binding protein villin. J Biol Chem 284 : 35278 35282.
247. Tsai MH, Hall A, Stacey DW (1989). Inhibition by phospholipids of the interaction between R-ras, rho, and their GTPase-activating proteins. Mol Cell Biol 9 : 5260 5264.
248. Tsuda S, Okudaira S, Moriya-Ito K, Shimamoto C, Tanaka M, Aoki J et al. (2006). Cyclic phosphatidic acid is produced by autotaxin in blood. J Biol Chem 281 : 26081 26088.
249. Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P et al. (2006). Different residues mediate recognition of 1-O- oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J Biol Chem 281 : 3398 3407.
250. Tsukahara T, Tsukahara R, Fujiwara Y, Yue J, Cheng Y, Guo H et al. (2010). Phospholipase D2-dependent Inhibition of the Nuclear Hormone Receptor PPARγ by Cyclic Phosphatidic Acid. Mol Cell 38.
251. Tsurudome M, Nishio M, Ito M, Tanahashi S, Kawano M, Komada H et al. (2008). Effects of hemagglutinin-neuraminidase protein mutations on cell-cell fusion mediated by human parainfluenza type 2 virus. J Virol 82 : 8283 8295.
252. Uchiyama A, Mukai M, Fujiwara Y, Kobayashi S, Kawai N, Murofushi H et al. (2007). Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochim Biophys Acta 1771 : 103 112.
253. Ueda H (2006). Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 109 : 57 77.
254. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K et al. (2002). Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158 : 227 233.
255. Valentine WJ, Fells JI, Perygin DH, Mujahid S, Yokoyama K, Fujiwara Y et al. (2008a). Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. J Biol Chem 283 : 12175 12187.
256. Valentine WJ, Fujiwara Y, Tsukahara R, Tigyi G (2008b). Lysophospholipid signaling: beyond the EDGs. Biochim Biophys Acta 1780 : 597 605.
257. Vial C, Zuniga LM, Cabello-Verrugio C, Canon P, Fadic R, Brandan E (2008). Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation. J Cell Physiol 215 : 410 421.
258. Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ et al. (2010). Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal 22 : 926 935.
259. Vincent MS, Leslie DS, Gumperz JE, Xiong X, Grant EP, Brenner MB (2002). CD1-dependent dendritic cell instruction. Nat Immunol 3 : 1163 1168.
260. Vincent MS, Gumperz JE, Brenner MB (2003). Understanding the function of CD1-restricted T cells. Nat Immunol 4 : 517 523.
261. Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM (2003). Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 23 : 3221 3233.
262. Wang A, Loo R, Chen Z, Dennis EA (1997). Regiospecificity and catalytic triad of lysophospholipase I. J Biol Chem 272 : 12723 12729.
263. Wang DA, Du H, Jaggar JH, Brindley DN, Tigyi GJ, Watsky MA (2002). Injury-elicited differential transcriptional regulation of phospholipid growth factor receptors in the cornea. Am J Physiol Cell Physiol 283 : C1646 C1654.
264. Wasserman MJ, Corson TW, Sibony D, Cooke RG, Parikh SV, Pennefather PS et al. (2004). Chronic lithium treatment attenuates intracellular calcium mobilization. Neuropsychopharmacology 29 : 759 769.
265. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J et al. (2007a). Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 41 : 616 623.
266. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T et al. (2007b). Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 81 : 1009 1015.
267. Weiner JA, Hecht JH, Chun J (1998). Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol 398 : 587 598.
268. Wendel AA, Lewin TM, Coleman RA (2009). Glycerol-3-phosphate acyltransferases: Rate limiting enzymes of triacylglycerol biosynthesis. Biochim Biophys Acta 1791 : 501 506.
269. Wetter JA, Revankar C, Hanson BJ (2009). Utilization of the Tango beta-arrestin recruitment technology for cell-based EDG receptor assay development and interrogation. J Biomol Screen 14 : 1134 1141.
270. Wiedmaier N, Muller S, Koberle M, Manncke B, Krejci J, Autenrieth IB et al. (2008). Bacteria induce CTGF and CYR61 expression in epithelial cells in a lysophosphatidic acid receptor-dependent manner. Int J Med Microbiol 298 : 231 243.
271. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W et al. (2009). Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem 284 : 17304 17319.
272. Xie Y, Gibbs TC, Mukhin YV, Meier KE (2002). Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 277 : 32516 32526.
273. Xie W, Matsumoto M, Chun J, Ueda H (2008). Involvement of LPA1 receptor signaling in the reorganization of spinal input through Abeta-fibers in mice with partial sciatic nerve injury. Mol Pain 4 : 46.
274. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang X-J SA et al. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1 : 1223 1232.
275. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM et al. (2009). Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 174 : 1264 1279.
276. Yakubu MA, Leffler CW (1999). Regulation of ET-1 biosynthesis in cerebral microvascular endothelial cells by vasoactive agents and PKC. Am J Physiol 276 (2 Pt 1 C300 C305.
277. Yamada T, Ohoka Y, Kogo M, Inagaki S (2005). Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). J Biol Chem 280 : 19358 19363.
278. Yanagida K, Ishii S, Hamano F, Noguchi K, Shimizu T (2007). LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem 282 : 5814 5824.
279. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y et al. (2009). Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 284 : 17731 17741.
280. Yang L, Andrews DA, Low PS (2000). Lysophosphatidic acid opens a Ca(++) channel in human erythrocytes. Blood 95 : 2420 2425.
281. Ye X (2008). Lysophospholipid signaling in the function and pathology of the reproductive system. Hum Reprod Update 14 : 519 536.
282. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK et al. (2005). LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435 : 104 108.
283. Ye X, Skinner MK, Kennedy G, Chun J (2008). Age-dependent loss of sperm production in mice via impaired lysophosphatidic acid signaling. Biol Reprod 79 : 328 336.
284. Yin Z, Watsky MA (2005). Chloride channel activity in human lung fibroblasts and myofibroblasts. Am J Physiol Lung Cell Mol Physiol 288 : L1110 L1116.
285. Yin Z, Tong Y, Zhu H, Watsky MA (2008). ClC-3 is required for LPA-activated Cl- current activity and fibroblast-to-myofibroblast differentiation. Am J Physiol Cell Physiol 294 : C535 C542.
286. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F et al. (2009). Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284 : 12328 12338.
287. Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J et al. (2003). Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 108 : 1746 1752.
288. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J et al. (2008). Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100 : 1630 1642.
289. Yue J, Yokoyama K, Balazs L, Baker DL, Smalley D, Pilquil C et al. (2004). Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell Signal 16 : 385 399.
290. Yuelling LM, Fuss B (2008). Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochim Biophys Acta 1781 : 525 530.
291. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM (1999). Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6 : 373 378.
292. Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR et al. (2004). Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med 199 : 763 774.
293. Zhang H, Bialkowska A, Rusovici R, Chanchevalap S, Shim H, Katz JP et al. (2007a). Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5. J Biol Chem 282 : 15541 15549.
294. Zhang H, Wang D, Sun H, Hall RA, Yun CC (2007b). MAGI-3 regulates LPA-induced activation of Erk and RhoA. Cell Signal 19 : 261 268.
295. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J et al. (2009a). Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 69 : 5441 5449.
296. Zhang Y, Qian Y, Lu W, Chen X (2009b). The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res 69 : 6049 6056.
297. Zhao Y, Usatyuk PV, Cummings R, Saatian B, He D, Watkins T et al. (2005). Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. Biochem J 385 (Pt 2 493 502.
298. Zheng Y, Voice JK, Kong Y, Goetzl EJ (2000). Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. FASEB J 14 : 2387 2389.
299. Zheng Y, Kong Y, Goetzl EJ (2001). Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 166 : 2317 2322.
300. Zhou D, Luini W, Bernasconi S, Diomede L, Salmona M, Mantovani A et al. (1995). Phosphatidic acid and lysophosphatidic acid induce haptotacic migration of human monocytes. J Biol Chem 270 : 25549 25556.